Page last updated: 2024-10-16

carbamates and Amentia

carbamates has been researched along with Amentia in 19 studies

Research Excerpts

ExcerptRelevanceReference
"Rivastigmine may improve the cognitive functions in PD patients with dementia with no worsening of motor function."9.10Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. ( Anca, M; Benbunan, B; Giladi, N; Gurevich, T; Korczyn, AD; Shabtai, H, 2003)
"65 patients suffering from AD, 10 from vascular dementia, and 15 from both were randomized to open label rivastigmine and risperidone, alone or in combination, for 20 weeks."9.10A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. ( Anand, R; Cicin-Sain, A; Hartman, R; Korczyn, AD; Rotmensch, HH; Weiser, M, 2002)
"Memantine, a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be effective in dementia, including Alzheimer disease (AD)."7.72Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. ( Hartmann, S; Möbius, HJ, 2003)
"The observation that patients with Parkinson's disease dementia have extensive cholinergic deficits led to the hypothesis that cholinesterase inhibitors may provide benefits for patients with this condition."5.31Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. ( Bullock, R; Cameron, A, 2002)
" We studied the effects of rivastigmine on the qEEG in Parkinson's disease (PD) patients with dementia."5.10Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. ( Fogelson, N; Giladi, N; Kogan, E; Korczyn, AD; Neufeld, MY; Shabtai, H, 2003)
"Rivastigmine may improve the cognitive functions in PD patients with dementia with no worsening of motor function."5.10Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. ( Anca, M; Benbunan, B; Giladi, N; Gurevich, T; Korczyn, AD; Shabtai, H, 2003)
"65 patients suffering from AD, 10 from vascular dementia, and 15 from both were randomized to open label rivastigmine and risperidone, alone or in combination, for 20 weeks."5.10A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. ( Anand, R; Cicin-Sain, A; Hartman, R; Korczyn, AD; Rotmensch, HH; Weiser, M, 2002)
" Pitolisant, a novel histamine-3 receptor antagonist/inverse agonist, gained approval for the treatment of excessive daytime sleepiness in adults with narcolepsy as well as obstructive sleep apnea."5.05New pharmacologic agents for insomnia and hypersomnia. ( Earl, DC; Van Tyle, KM, 2020)
"Memantine, a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be effective in dementia, including Alzheimer disease (AD)."3.72Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. ( Hartmann, S; Möbius, HJ, 2003)
"Cholinesterase inhibitors (ChEIs) are dosed in two phases for the treatment of dementia, an initial dose-escalation phase to achieve a therapeutic dose and a maintenance phase where the therapeutic dose is given for long-term therapy."2.41The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. ( Inglis, F, 2002)
" Rivastigmine shows a clear dose-response relationship, and physicians should aim to maintain patients on doses of 6 mg/day or higher, to a maximum of 12 mg/day."2.41The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. ( Bullock, R, 2002)
"The observation that patients with Parkinson's disease dementia have extensive cholinergic deficits led to the hypothesis that cholinesterase inhibitors may provide benefits for patients with this condition."1.31Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. ( Bullock, R; Cameron, A, 2002)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19904 (21.05)18.7374
1990's1 (5.26)18.2507
2000's12 (63.16)29.6817
2010's1 (5.26)24.3611
2020's1 (5.26)2.80

Authors

AuthorsStudies
Earl, DC1
Van Tyle, KM1
Lin, JN1
Lin, CL1
Lin, MC1
Lai, CH1
Lin, HH1
Yang, CH1
Kao, CH1
Rösler, M1
Inglis, F1
Bullock, R2
Cameron, A1
Hartmann, S1
Möbius, HJ1
Fogelson, N1
Kogan, E1
Korczyn, AD3
Giladi, N2
Shabtai, H2
Neufeld, MY1
Werber, EA1
Gandelman-Marton, R1
Klein, C1
Rabey, JM1
GIBBS, AE1
WYKES, PR1
D AMELIO, V1
ANNOVI, G1
Fuchsberger, T1
Möller, HJ1
Hampel, H1
Gurevich, T1
Benbunan, B1
Anca, M1
Schneider, LS1
Smith, DJ1
Yukhnevich, S1
Weiser, M1
Rotmensch, HH1
Hartman, R1
Cicin-Sain, A1
Anand, R1
Tewfik, GI1
Jain, VK1
Harcup, M1
Magowan, S1

Reviews

7 reviews available for carbamates and Amentia

ArticleYear
New pharmacologic agents for insomnia and hypersomnia.
    Current opinion in pulmonary medicine, 2020, Volume: 26, Issue:6

    Topics: Azepines; Carbamates; Dementia; Disorders of Excessive Somnolence; GABA-A Receptor Agonists; Humans;

2020
The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
    International journal of clinical practice. Supplement, 2002, Issue:127

    Topics: Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans

2002
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
    International journal of clinical practice. Supplement, 2002, Issue:127

    Topics: Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Nootropic A

2002
[Current therapy of patients with dementia].
    MMW Fortschritte der Medizin, 2003, May-26, Volume: 145 Suppl 2

    Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Controlled Cli

2003
New therapeutic approaches to cognitive impairment.
    The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 11

    Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; D

1998
Understanding changes in cholinergic function: implications for treating dementia.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:3

    Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinergic Fibers; Cholinesterase Inhibi

2002
The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
    International journal of clinical practice, 2002, Volume: 56, Issue:3

    Topics: Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Dementia; Hum

2002

Trials

5 trials available for carbamates and Amentia

ArticleYear
Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients.
    Acta neurologica Scandinavica, 2003, Volume: 107, Issue:4

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Carbamates; Cholinesterase Inhibitors; Dementia; Elec

2003
The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients.
    Journal of neural transmission (Vienna, Austria : 1996), 2003, Volume: 110, Issue:6

    Topics: Acetylcholine; Aged; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Cognition Disorders; De

2003
Rivastigmine (Exelon) for dementia in patients with Parkinson's disease.
    Acta neurologica Scandinavica, 2003, Volume: 108, Issue:5

    Topics: Aged; Carbamates; Cholinesterase Inhibitors; Cognition; Dementia; Humans; Male; Parkinson Disease; P

2003
A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances.
    International journal of geriatric psychiatry, 2002, Volume: 17, Issue:4

    Topics: Aged; Analysis of Variance; Antipsychotic Agents; Carbamates; Cholinesterase Inhibitors; Dementia; D

2002
Effectiveness of various tranquilisers in the management of senile restlessness.
    Gerontologia clinica, 1970, Volume: 12, Issue:6

    Topics: Aged; Carbamates; Chlorpromazine; Clinical Trials as Topic; Dementia; Female; Haloperidol; Humans; H

1970

Other Studies

7 other studies available for carbamates and Amentia

ArticleYear
Increased Risk of Dementia in Patients With Acute Organophosphate and Carbamate Poisoning: A Nationwide Population-Based Cohort Study.
    Medicine, 2015, Volume: 94, Issue:29

    Topics: Adult; Aged; Carbamates; Cohort Studies; Dementia; Female; Humans; Incidence; Insecticides; Insuranc

2015
Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
    Current medical research and opinion, 2002, Volume: 18, Issue:5

    Topics: Aged; Carbamates; Cholinesterase Inhibitors; Dementia; Female; Hallucinations; Humans; Male; Parkins

2002
Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.
    International clinical psychopharmacology, 2003, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Dose-Res

2003
The use of methylpentynol carbamate in a geriatric unit.
    Proceedings of the staff meetings. Mayo Clinic, 1960, Volume: 35

    Topics: Carbamates; Dementia; Geriatrics; Humans; Mental Disorders; Psychotic Disorders

1960
Sedation in geriatrics using methylpentynol carbamate.
    The Practitioner, 1960, Volume: 184

    Topics: Aged; Carbamates; Dementia; Geriatrics; Humans; Hypnotics and Sedatives; Mental Disorders; Psychotic

1960
[TREATMENT WITH MEBUTAMATE (AN ANTIHYPERTENSIVE WITH CENTRAL ACTION) OF MENTAL PATIENTS WITH HYPERTENSIVE MANIFESTATIONS].
    Gazzetta medica italiana, 1963, Volume: 122

    Topics: Alcoholism; Antihypertensive Agents; Anxiety; Bipolar Disorder; Carbamates; Dementia; Epilepsy; Huma

1963
Adverse reactions to rivastigmine in three cases of dementia.
    The Australian and New Zealand journal of psychiatry, 2001, Volume: 35, Issue:5

    Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Alzheimer Disease; Carbamates; Cholinesterase Inhi

2001